The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations-Reference-Cited by-同舟云学术

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations

Published:2016-12-03 Issue:2 Volume:8 Page:3412-3421
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lin Jing-Hui¹²,Lin Dong¹²,Xu Ling¹²,Wang Qiang¹²,Hu Hui-Hua¹²,Xu Hai-Peng¹²,He Zhi-Yong¹²

Affiliation:

1. Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China

2. Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors;Respiratory Medicine and Research;2023-11

2. Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation;Applied Immunohistochemistry & Molecular Morphology;2023-06-20

3. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis;BMC Pulmonary Medicine;2023-06-14

4. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non–Small-Cell Lung Cancer: A Meta-Analysis;JCO Precision Oncology;2023-05

5. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2022-09